Lyell Immunopharma (LYEL) Cash from Investing Activities (2020 - 2026)

Lyell Immunopharma has reported Cash from Investing Activities for 7 years, with the latest figure at $17.4 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 74.98% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 98.82% YoY) and the FY2025 annual result came in at $54.1 million, down 55.81% from the prior year.
• Cash from Investing Activities climbed to $17.4 million in Q1 2026 per LYEL's latest filing, from -$31.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $152.9 million in Q2 2023 and troughed at -$100.7 million in Q4 2023.
• A 5-year average of $21.6 million and a median of $22.0 million in 2024 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 511.18% in 2023, down 315.85% in 2023.
• Over 5 years, Cash from Investing Activities stood at $46.6 million in 2022, then tumbled by 315.85% to -$100.7 million in 2023, then soared by 153.14% to $53.5 million in 2024, then tumbled by 158.62% to -$31.4 million in 2025, then surged by 155.41% to $17.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $17.4 million, -$31.4 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.